Navigation Links
BioMS Medical to present at Alberta Economic Forum in Geneva
Date:4/29/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, April 29 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at a session entitled "Leveraging on energy wealth: the development of a world class technology sector" as part of the Alberta Economic Forum in Geneva in Switzerland.

    WHEN:     Monday May 4th at 10:05am (Local time)

    WHERE:    Grand Hotel Kempinski, Geneva, Switzerland

    About Alberta Economic Forum
    ----------------------------

The Alberta Economic Forum will profile direct and financial investment opportunities while also addressing the environmental, economical and technological issues critical to the long term success of investment in Alberta. With an anticipated 300 attendees, participants of the forum will include investment bankers, portfolio managers, independent wealth managers, private investors, financial analysts, and portfolio managers from both Europe and Canada, in addition to senior managers of the infrastructure sector and government. For more information visit http://www.albertaeconomicforum.com/

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 21, 2017 , ... Beaker, ... executive talent in the life sciences industry, today announces a strategic partnership with ... partnership takes full advantage of Beaker’s expertise in executive recruitment solutions, providing Alcami ...
(Date:6/22/2017)... ... , ... Building on the success of the inaugural RAADfest last year, RAADfest ... developments in radical life extension. RAADfest combines cutting edge science presented for a lay ... development, making it the largest most comprehensive and inclusive super longevity event in the ...
(Date:6/22/2017)... ... June 22, 2017 , ... Ovation Fertility supports the ... disease, bringing new hope for prospective parents who are challenged with costs of ... the World Health Organization’s designation in hopes of changing the way health insurers, ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... to clients throughout the biopharma and life sciences industries, continue to be in ... seeing. Tunnell’s Kip Wolf will be speaking on “The State of Information Governance ...
Breaking Biology Technology:
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
Breaking Biology News(10 mins):